CLINICAL_TRIALS
trial_result
· 2024-12-24
Clinical Trial Update: ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer [Phase 2]
Summary
A Phase 2 study of ONC201 in recurrent Type II endometrial cancer was terminated, with results posted on 2024-12-24.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jazz Pharmaceuticals | Conditions: Endometrial Cancer Recurrent | Phase 2 | Status: TERMINATED | Results posted: 2024-12-24